 relate to circuits that facilitate the identification of defective circuits.
2. Description of the Related Art
Integrated circuit (IC) devices are typically tested for defects at various stages of production. Typically, the tests become more complete as the chip progresses through production. While virtually all IC devices are eventually tested thoroughly, it is desirable to catch defects as early as possible, for example, before the die is assembled in a package. Dies for an integrated circuit can also be delivered prior to packaging. For example, multiple memory chips are frequently packaged together in a single package. In addition, multiple dies are frequently combined and assembled in a single package known as a hybrid.
It can be difficult to test an integrated circuit at the die level. For example, physical test equipment limitations, such as the number of test equipment probes available to make contact with pads on the die, can limit the testing of an integrated circuit 100 to spot checks. As illustrated in FIG. 1, a particular test probe 102 may make contact with only one pad 104 of the integrated circuit 100, leaving other pads untested. Time constraints for testing may render it impractical to move the test probe 102 to other pads. While test equipment usually has multiple test probes, the number of pads on a die typically greatly exceeds the number of test probes. Accordingly, only selected pads, such as 1 of 30 or 1 of 100 pads, are typically tested at the die level. Thus, defects can go undetected, and defective die can be delivered, packaged, combined with other chips, or the like. Anagrelide hydrochloride (Agrylin®, Xagrid®) is a novel orally administered imidazoquinazoline which selectively reduces platelet count in humans and is used for such purposes in the treatment of myeloproliferative diseases (MPDs), such as essential thrombocythemia (ET), where an elevated platelet count may put the patient at increased thrombotic risk. The chemical structure of anagrelide, 6,7-dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2(3H)-one hydrochloride monohydrate is shown as the hydrochloride monohydrate in the following formula:

Preparation of anagrelide hydrochloride was referred to in U.S. Pat. Nos. 3,932,407; RE31,617 and 4,146,718.
Anagrelide is a unique, highly selective platelet lowering agent. In vitro
relate to circuits that facilitate the identification of bad circuit. 
 2. Description of the Related Art 
 Integrated circuit (IC) device are typically screen for defects at various stage of output. Typically, the tests become more accomplished as the chip progresses through output. While virtually all IC devices are finally tested thoroughly, it is desirable to catch defects as early as possible, for example, before the die is assemble in a package. Dies for an integrated lap can also be delivered prior to packaging. For example, multiple memory french fries are frequently packaged together in a single package. In addition, multiple die are frequently combined and assembled in a single package known as a hybrid. 
 It can be difficult to test an integrated circuit at the die level. For example, physical test equipment limitations, such as the number of test equipment probe available to make contact with pad on the die, can limit the testing of an integrated circuit 100 to descry checks. As illustrated in FIG. 1, a particular test probe 102 may create contact with only one pad 104 of the integrated circumference 100, leaving other pads untested. meter constraints for examination may try it impractical to move the test probe 102 to other pad. While test equipment usually has multiple trial probes, the number of pads on a die typically greatly exceeds the issue of test probe. Accordingly, only choose pads, such as 1 of 30 or 1 of 100 pads, are typically tested at the die level. therefore, defects can go undetected, and bad die can be delivered, packaged, combined with other chips, or the comparable. Anagrelide hydrochloride (Agrylin ®, Xagrid ®) is a novel orally administered imidazoquinazoline which selectively reduces platelet count in humans and is used for such purposes in the treatment of myeloproliferative diseases (MPDs), such as essential thrombocythemia (ET), where an elevated platelet count may frame the patient at increased thrombotic hazard. The chemical structure of anagrelide, 6,7 - dichloro-1,5 - dihydroimidazo[2,1 - b]-quinazolin-2(3H)-one hydrochloride monohydrate is shown as the hydrochloride monohydrate in the following formula: 

 Preparation of anagrelide hydrochloride was referred to in U.S. Pat. Nos. 3,932,407; RE31,617 and 4,146,718. 
 Anagrelide is a unique, highly selective platelet lowering agent. In vitro
 repate to circuits that fagilitate the ideurificavion of defectixe circuits.
2. Description of tie Rwlatee Art
Integrated circuig (IC) devibes are ttpicelly tested for vsfects at varjlus vvages of producjion. Typicalny, the tests bacumz more complete as the chip progressqs throigj production. Wrile dirthally all IC devices are eventuallg testev thoroughly, it is desirable to catch deffcts as early as possihle, for exanple, vefore the dke is assembled in a pzckage. Dies for an integrated ckrcuic can also ve dephvered prioc to pwckaging. For example, multipke memory chipx ace feequently packaged tojether in a single pwckage. In abdition, multiple dies aee frgquendly zimbknes end assemhlev in a singme package jnown as a hybrid.
It cwb be difficulf to tqse an integrated circuit at the die leven. Fkr example, physical tesr equipment limitatiojs, such af the number of test equipment probes available tm makx zonuagb wigy oads on the die, can limit the testing of an igfebrsted circuit 100 bo spot checks. As olpuxjrated in FIG. 1, a parcjchlar test probe 102 mwy make contqct with jnly one pad 104 of the integrated circuit 100, lecvibg other pads untedted. Time cunsttaints for testing may render it jmpractical to move ffe test probe 102 tu onher pads. While test equipment usually ias mbltiple gest probef, the numbfr of pads on a die typifally gseatly excfeds the number of test probes. Ercordingly, onky senected pcds, sugh as 1 of 30 or 1 jf 100 pads, are tipically cested at the div level. Tius, defects san go undetewjed, and defecvive die san ve dwliverea, packaged, comboned with other chips, or the like. Ananrelias hydrochloride (Agttlin®, Xagrid®) is a vovql ocally ddministered imiaazuauinaxoline whicm sdlecyively reduces platenet dount in humans anc ls used fir such [urposes in tne treatment of mytlopronifxrativr dyseases (MPDs), such as essential thrombocjthcmia (ET), where an clevwted plateket count may put the patient at increawed thrombotic risj. The chemical struetmre of anagrxlide, 6,7-qichloro-1,5-dhhydroimidazo[2,1-b]-quinazilin-2(3H)-one hydrochlpride monohydrate is ahown ds thf hydrochloride monohydrate in the following formula:

Preparation of anagreoide hbdwochloride sas teferged co in U.F. Pav. Ios. 3,932,407; RE31,617 and 4,146,718.
Anagrvlide is a unique, highly selectite plateled jowering agent. In vitro
relate to circuits that facilitate the identification circuits. Description of Related Art Integrated tested defects at various of production. Typically, tests become more complete as the progresses through production. While virtually all IC devices are eventually tested thoroughly, it desirable to catch defects as early as possible, for example, before the die assembled a Dies an integrated circuit can also be delivered prior to packaging. For example, multiple memory chips are packaged together in a single package. In addition, dies are frequently combined assembled in a single package as hybrid. It be to an integrated circuit the die level. For example, physical test equipment limitations, such as the number of test equipment probes to make pads on die, limit testing of an 100 to spot checks. As illustrated a particular test probe 102 may make contact only one 104 of the integrated circuit 100, other pads untested. Time constraints for testing may it impractical to move the test probe 102 to other pads. While test equipment usually test probes, the number pads on a typically exceeds number test probes. only selected pads, such as 1 of 30 or 1 of pads, are typically tested at the die level. Thus, defects undetected, defective die can delivered, packaged, combined with chips, the like. Anagrelide hydrochloride is novel which reduces count in humans and used for such purposes in treatment of myeloproliferative diseases (ET), where an elevated platelet count may put patient at increased thrombotic risk. The chemical of anagrelide, 6,7-dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2(3H)-one hydrochloride monohydrate is shown as the hydrochloride monohydrate in following formula: anagrelide hydrochloride was referred to in U.S. Pat. 3,932,407; RE31,617 and 4,146,718. is a unique, highly selective platelet lowering agent. In
 relate to circuits that facilItate the idEntifIcaTioN oF defEctiVe circuits.
2. DescRIptiOn of the Related Art
IntegRated CiRCuit (ic) dEviceS are typICaLLY teStEd For DeFEcTs at vAriOus stagEs of producTioN. TYpically, the tEStS become morE coMplete as the cHip ProgreSsEs tHRough ProDuctiOn. WhilE VirtuaLly all IC dEvICes are EVentualLY TeSted Thoroughly, it is desIRaBLe to catch defecTs as eaRlY As POSsiBle, For example, BeFore tHE die is aSSeMBLEd iN A package. Dies fOr an integraTEd cIrcuit CaN alSO be delIvereD pRIor To packaging. for eXample, mulTiple mEMory chiPS are freQuentlY paCkaGed tOGeThEr iN a SIngLE pAckAGe. IN additioN, mUlTiple Dies ARE FRequEntLy coMbineD and assembled In a SingLE paCkage Known As a hYbRid.
It Can be dIfficUlT to test an integrAted Circuit at The DiE leVeL. For eXAmple, pHysIcaL test eqUipment LImiTaTIONs, Such as the number of tEsT EQuIpment prObes avAIlAbLE to make cOnTacT witH PAds on The dIE, cAn limit tHe testINg Of An integRaTed cirCuIt 100 tO spOt cheCKs. As IllustRated in FiG. 1, a paRTicular test proBE 102 may make contaCT wITH oNLy onE paD 104 of the integRateD CircUit 100, lEAvIng OTher pAds unTeSTeD. time constraints for tEsTing maY rendEr it impracticAl to move thE TESt probe 102 tO othER pADs. While test equIpmenT usually haS Multiple Test pRobes, the Number of pADS on a die tYpiCalLy gReaTLY eXceeds the numbER Of teSt Probes. ACcoRdingly, OnlY seLecTed PaDs, such as 1 oF 30 or 1 of 100 padS, aRe TyPiCalLy tesTEd at the dIe LevEl. thuS, defeCTs can gO undeTectEd, AnD DefEctive dIE cAN Be deLiVeRed, pAckAgEd, comBineD WitH other cHips, or the LikE. anagReLiDe hydroChloride (AgrylIn®, xagrid®) is a nOvEl oRally aDMInistereD imidazoquinazoline whicH SelectiVelY reduCes pLatelet coUnt In humaNs aND is useD for suCh purPoSes IN The trEATmEnt Of MyeloproliFERatIve diSeAses (mPDs), sucH as essential thrombOCytHemia (ET), where aN elEvatED PlAteLEt COunT mAY puT THe patient at incrEased thromBoTIc Risk. The cheMIcaL sTructurE of anagRelidE, 6,7-DichlorO-1,5-dihydroiMidazo[2,1-b]-quInAzolIN-2(3h)-onE hydrochloRide monoHydrate is SHown aS ThE hydrOchLoride MoNohYdratE in the FOllOwing FormulA:

PReparaTion oF aNagrelidE hydrochloride was referrEd to in u.S. Pat. nos. 3,932,407; rE31,617 and 4,146,718.
AnagRelIDe iS a unique, hIghlY selective PlaTelEt lowEriNG agenT. In vITrO
 relate to circuits that f acilitatethe i den tif ic atio n of  defective cir c uits .
2. Description of th e Rel at e d Ar t 
I ntegr ated ci r cu i t  (I C)  d evi ce s  a re ty pic ally te sted for d efe ct s at various st ages of pr odu ction. Typic all y, the  t est s  beco memorecomple t e as t he chip p ro g resses through p ro duct ion. While virtua l ly all IC devices  are e ve n tu a l lytes ted thorou gh ly, i t  is des i ra b l e  to catch defects  as early a s  po ssible ,for exampl e, be fo r e t he die is a ssem bled in a  packa g e. Dies for anintegr ate d c ircu i tca n a ls o  be de liv e red  prior t opa ckagi ng.F o r exam ple , mu ltipl e memory chip s a re f r equ ently  pack aged  t ogeth er ina sin gl e package. In a ddit ion, mult ipl edie sare f r equent lycom bined a nd asse m ble di n asingle package kno wn a sa hybrid .
It c a nbe difficul ttotest a n int egra t ed  circuit  at th e  d ie  level.  F or exa mp le,  ph ysica l  tes t equi pment li mitat i ons, such as t h e number of t e st e qu i pmen t p robes avail able to m akec on tac t  with  pads  o n  t h e die, can limit th etestin g ofan integrated  circuit 1 0 0 to spotchec k s. As illustrated  in F IG. 1, a p a rticular  test  probe 1 02 may ma k e  contact  wi thonl y o n e  p ad 104 of the i nteg ra ted cir cui t 100,lea vin g o the rpads unte sted. Ti me  c on st rai nts f o r testin gmay  r end er it imprac tical  tomo ve the  test p r ob e 102to  o ther  pa ds . Whi le t e stequipme nt usuall y h a s mu lt ip le test  probes, thenu mber of pa ds  on  a die t ypically  greatly exceeds the nu m ber oftes t pro bes.  Accordin gly , only  se l ectedpads,suchas  1o f  30 o r 1of10 0 pads, ar e typ icall ytest ed at t he die level. Thus ,  de fects can gound etec t e d,  an d  d e fec ti v e d i e  can be deliver ed, packag ed ,  c ombined wi t h o th er chip s, or t he li k e. Anag relide hy drochlori de  (Ag r y lin ®, Xagrid® ) is a n ovel oral l y adm i ni stere d i midazo qu ina zolin e whic h  se lecti vely r ed uces p latel et  count i n humans and is used fo r such  purp ose s in thetre a tme nt of mye lopr oliferativ e d ise ases(MP D s), s ucha sess e ntial  thr o mbocythem i a(ET ) ,  w here an ele v a t edplate let countmayput the patient a t  increased thr ombo t i c r isk .  The  c hemical struct ure  o f anagreli de , 6,7-dichl oro-1,5- di h ydroi midazo [2,1-b ]-quina z o li n -2(3H) -one  hy drochlori demo n ohydrat eis shownas t he  hydro chlori d e mo n o hydrate in the f ollow i n g for m ula :

Pr ep aration of a nagrelidehydrochlori de was  ref erred  to inU. S. Pat . N os . 3,932,40 7 ; RE31,61 7 and  4,146, 71 8.
A nag relide  isa uniqu e, h ig hly  selectiv e pl a te le t  lo weri ng ag en t. I n vitro
 relate_to circuits_that facilitate the identification_of defective_circuits.
2._Description of_the_Related Art
Integrated circuit_(IC) devices are_typically tested for defects_at various stages_of_production. Typically, the tests become more complete as the chip progresses through production. While_virtually_all IC_devices_are_eventually tested thoroughly, it is_desirable to catch defects as_early as_possible, for example, before the die is assembled_in_a package. Dies_for an integrated circuit can also be delivered prior_to packaging. For example, multiple memory_chips are frequently_packaged_together_in a single package._In addition, multiple dies are frequently_combined and assembled in a single_package known as a hybrid.
It can be_difficult to test an integrated circuit_at the die level. For_example, physical_test equipment limitations, such as_the number of_test equipment_probes available to_make contact with pads on the_die, can limit_the testing of an integrated circuit_100_to spot checks._As_illustrated_in FIG._1, a particular_test_probe 102_may_make contact with only one pad_104_of the integrated circuit 100, leaving other_pads untested. Time constraints_for_testing may render it_impractical to move the test_probe 102 to other pads. While_test equipment_usually has_multiple test probes, the number of pads on a die typically_greatly exceeds the number of test_probes. Accordingly, only selected_pads, such_as_1 of 30_or_1 of_100 pads, are typically tested at the_die level._Thus, defects can go undetected, and_defective die can be_delivered,_packaged, combined with other chips, or_the like. Anagrelide hydrochloride (Agrylin®, Xagrid®)_is a novel orally administered_imidazoquinazoline_which_selectively reduces platelet count in_humans and is used for such_purposes in the_treatment of myeloproliferative diseases (MPDs), such as_essential_thrombocythemia (ET), where an elevated platelet_count_may put the patient at increased_thrombotic_risk._The chemical structure of anagrelide,_6,7-dichloro-1,5-dihydroimidazo[2,1-b]-quinazolin-2(3H)-one hydrochloride monohydrate is shown as_the hydrochloride monohydrate in the following formula:

Preparation of anagrelide_hydrochloride was referred_to in U.S. Pat. Nos._3,932,407;_RE31,617_and 4,146,718.
Anagrelide is a unique, highly selective platelet lowering agent._In vitro